drug resistance – Page 4

Antifungal effect of soil Bacillus bacteria on pathogenic species of the fungal genera Aspergillus and Trichophyton

mycolabadmin

Researchers discovered that four types of Bacillus bacteria found in soil can effectively kill dangerous fungi that cause infections in humans. These bacteria produce natural compounds that inhibit fungal growth even better than some standard antifungal medications. This discovery is particularly important because many fungi are becoming resistant to current drugs, making these soil bacteria a promising natural alternative for treating fungal infections.

The efficacy of luliconazole and caspofungin on planktonic and biofilm of Candida albicans from different sources

mycolabadmin

Candida albicans, a common yeast infection organism, can form tough protective structures called biofilms that resist antifungal medications. This study tested two antifungal drugs (luliconazole and caspofungin) against Candida in both regular form and biofilm form. The results showed that while these drugs work well against regular Candida cells, they are much less effective against biofilms, which require 15-171 times higher doses to be inhibited. The strongest biofilms came from vaginal infections, suggesting that different infection types may require different treatment approaches.

Caged-hypocrellin mediated photodynamic therapy induces chromatin remodeling and disrupts mitochondrial energy metabolism in multidrug-resistant Candida auris

mycolabadmin

Researchers developed a new photodynamic therapy treatment using a light-activated compound called COP1T-HA to fight drug-resistant Candida auris infections. The therapy works by reorganizing the fungal cell’s genetic material architecture and disrupting energy production in mitochondria, ultimately killing the fungal cells. This approach represents a novel strategy to overcome antibiotic resistance, as it targets multiple cellular processes rather than a single pathway that fungi can easily resist.

Clinical Mycology Today: Emerging Challenges and Opportunities

mycolabadmin

Fungal infections are becoming more common due to new cancer treatments and other medical advances, while some fungal species are developing resistance to standard antifungal medications. The good news is that several new antifungal drugs are in development with better safety profiles and novel mechanisms to fight these infections. However, the field faces challenges including limited specialized mycologists and difficulty designing clinical trials to properly test new treatments.

Staurosporine as an Antifungal Agent

mycolabadmin

Staurosporine is a natural compound produced by soil bacteria that can kill fungi. Scientists originally discovered it in 1977 and found it works by blocking proteins called kinases that fungi need to survive. Recent research shows it could be useful against drug-resistant fungal infections, especially when combined with other antifungal medicines. However, it needs to be modified to make it safer for human use.

Trichosporon Urinary Tract Infections: A Hidden Menace Revealed

mycolabadmin

Trichosporon is a fungus that causes urinary tract infections primarily in hospitalized patients and those with weakened immune systems. This review found that Trichosporon asahii is the most common species responsible for these infections, especially in patients with prolonged hospital stays or using immunosuppressive medications. The drug voriconazole works best against this fungus, while some common antifungal medications like amphotericin B are less effective. Accurate identification using modern laboratory techniques is crucial for proper treatment.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection of his heart valve after receiving an artificial valve replacement. The initial antibiotic (itraconazole) did not work because the fungus became resistant, likely by forming a protective biofilm. After identifying the resistant fungus through specialized testing, doctors switched to a different medication called caspofungin. The patient fully recovered with this new treatment and remained healthy during follow-up, showing that combination of precise identification and targeted treatment can overcome antibiotic resistance.

A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistant Candida auris infection

mycolabadmin

Researchers tested a new drug called APC6 that works by trapping zinc, which fungi need to survive. In mouse studies of a dangerous resistant fungus called Candida auris, APC6 saved all treated mice while most untreated mice died. The drug also reduced fungal infections in organs without causing serious side effects, suggesting it could become a new treatment option for serious fungal infections resistant to current medicines.

Things you wanted to know about fungal extracellular vesicles (but were afraid to ask)

mycolabadmin

Fungal extracellular vesicles (EVs) are tiny packages released by fungal cells that play important roles in fungal infections and how our immune system responds to them. Scientists have confirmed these EVs are real biological structures, not laboratory artifacts, and discovered they are produced by many different fungal species. Interestingly, these EVs can have opposite effects on the immune system depending on the fungus involved—sometimes helping our bodies fight infection and sometimes making infections worse, making them both potential vaccines and virulence factors.

Synergistic Effects of Cold Atmospheric Multiple Plasma Jet and Amphotericin B on Leishmania major: An In-Vitro Study

mycolabadmin

Researchers tested a new cold plasma technology combined with an existing anti-parasite drug (amphotericin B) against Leishmania parasites that cause skin infections. The cold plasma, which contains reactive chemicals, killed the parasites by triggering their programmed cell death (apoptosis) while causing minimal harm to human immune cells. When combined with the medication, the treatment was even more effective, potentially allowing lower drug doses with fewer side effects.

Research Topic: drug resistance